WINTON GROUP Ltd Invests $5.73 Million in Ralliant Corporation $RAL

WINTON GROUP Ltd acquired a new position in Ralliant Corporation (NYSE:RAL) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 112,521 shares of the company’s stock, valued at approximately $5,728,000.

Other institutional investors have also recently made changes to their positions in the company. Danske Bank A S bought a new position in shares of Ralliant in the 4th quarter worth approximately $25,000. V Square Quantitative Management LLC bought a new position in shares of Ralliant in the 4th quarter worth approximately $26,000. Allworth Financial LP lifted its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the period. Palisade Asset Management LLC bought a new position in shares of Ralliant in the 3rd quarter worth approximately $26,000. Finally, UMB Bank n.a. bought a new position in shares of Ralliant in the 3rd quarter worth approximately $29,000.

Ralliant Trading Down 3.6%

Ralliant stock opened at $60.18 on Friday. The stock has a market cap of $6.74 billion and a P/E ratio of -5.50. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.61 and a quick ratio of 1.05. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $63.31. The firm’s 50 day moving average price is $50.75 and its 200-day moving average price is $49.20.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The firm had revenue of $534.60 million for the quarter. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, equities analysts predict that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on RAL shares. Oppenheimer increased their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 13th. Truist Financial restated a “buy” rating and set a $68.00 target price (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. TD Cowen raised their target price on shares of Ralliant from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 20th. Wall Street Zen cut shares of Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, May 31st. Finally, Royal Bank Of Canada raised their target price on shares of Ralliant from $47.00 to $64.00 and gave the stock a “sector perform” rating in a research note on Wednesday, May 13th. Six investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Ralliant has an average rating of “Hold” and an average target price of $64.50.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.